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Abstract
Deep venous thrombosis prophylaxis is essential to the appropriate management of multisystem trauma patients.
Without thromboprophylaxis, the rate of venous thrombosis and subsequent pulmonary embolism is substantial.
Three prophylactic modalities are common: pharmacologic anticoagulation, mechanical compression devices, and
inferior vena cava filtration. A systematic review was completed using PRISMA guidelines to evaluate the potential
complications of DVT prophylactic options. Level one evidence currently supports the use of low molecular weight
heparins for thromboprophylaxis in the trauma patient. Unfortunately, multiple techniques are not infrequently
required for complex multisystem trauma patients. Each modality has potential complications. The risks of heparin
include bleeding and heparin induced thrombocytopenia. Mechanical compression devices can result in local soft
tissue injury, bleeding and patient non-compliance. Inferior vena cava filters migrate, cause inferior vena cava
occlusion, and penetrate the vessel wall. While the use of these techniques can be life saving, they must be appro-
priately utilized.
Introduction
Multisystem traumatic injury is a significant risk factor
for the development of a deep venous thrombosis
(DVT). Without thromboprophylaxis, overall DVT rates
exceed 50% [1-3]. Although DVT alone is not life-threa-
tening, a resulting pulmonary embolism (PE) carries
potentially significant morbidity and mortality. PE is
estimated to be the third leading cause of death in
injured patients who survive beyond the first day of
admission [2,4-6]. Trauma patients at the highest risk
have been identified as those with a lower extremity or
pelvic fracture, spinal cord injury, brain injury (Glasgow
Coma Score < 8), increased age, surgical intervention,
femoral central venous catheter, and prolonged immobi-
lization [2,3,7-9].
Modalities available for trauma patient thrombopro-
phylaxis are classified into pharmacologic anticoagula-
tion, mechanical compression devices, and inferior vena
cava (IVC) filtration. Although the options are numer-
ous, level one evidence currently supports the use of
pharmacologic anticoagulation with low molecular
weight heparins (LMWHs) as the primary DVT prophy-
lactic agent [10]. Other modalities such as mechanical
compression devices and IVC filters are not used for
primary thromboprophylaxis, but may be helpful when
LMWHs are contraindicated. This systematic review
describes the potential complications associated with
LMWHs, mechanical compression devices, and IVC
filters.
Methods
All scientific publications discussing the use of biochem-
ical, mechanical, and IVC filter prophylaxis for the pre-
v e n t i o no fD V Ta f t e rt r a u m aw e r ei d e n t i f i e du s i n g
PubMed, EMBASE, and Medline. Search terms included:
“DVT”, “deep venous thrombosis”, “complications”,
“trauma”, “injury”, “DVT prophylaxis”, “low molecular
weight heparin”, “heparin”, “chemical”, “mechanical”,
“IVC filter” and/or “heparin-induced thrombocytopenia.”
The Preferred Reporting Items for Systematic reviews
and Meta-Analyses (PRISMA) was employed. Only Eng-
lish language publications were included. Once identi-
fied, manuscripts were reviewed for relevance to the
topic of DVT prophylaxis, and sorted according to their
prophylactic mode of choice. This review included all
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any medium, provided the original work is properly cited.trauma related studies (qualitative and quantitative ana-
lysis), as well as some publications describing non-
trauma patients (qualitative comparisons). More specifi-
cally, 274 publications were identified through database
searching. After removing non-English and duplicate
manuscripts, 268 publications were available for poten-
tial analysis. Of these, 26 publications explicitly
described an analysis/reporting of potential complica-
tions secondary to DVT prophylaxis techniques in an
injured patient population. These 26 manuscripts were
included in a quantitative synthesis/review. An addi-
tional 53 publications were also included in the review
for qualitative discussion (non-trauma patients). Pooled
data was limited to complication risks for each modality.
Clinical heterogeneity was unavoidable across studies
with the most significant variance potentially due to the
severity of injury in blunt injured patients. Because it is
unknown if injury severity affects associated DVT pro-
phylaxis complication rates, pooled summary data was
not adjusted. We believe this offers a more broad
analysis.
Low Molecular Weight Heparins
LMWHs are generated from the chemical depolymeriza-
tion of unfractionated heparin (UH). This reduces their
size, charge, and weight [11]. Both LMWHs and UHs
inhibit thrombin (IIa), however LMWHs have signifi-
cantly greater activity towards factor Xa secondary to
their smaller size [11]. LMWHs are also less likely to
exhibit non-specific binding to endothelium, macro-
phages, and heparin-binding plasma proteins [11],
thereby increasing their bioavailability and half-life.
Finally, they also reduce the incidence of heparin-
induced thrombocytopenia (HIT), and provide a more
predictable dose-dependent response.
In trauma patients with a minimal injury severity
score (ISS) of 9, and without intracranial hemorrhage,
ongoing bleeding or coagulopathy, level one evidence
supports the use of enoxaparin (LMWH) as the primary
DVT prophylactic modality. In randomizing 265 patients
to receive either enoxaparin or UH, Geerts et al. [10]
demonstrated a significant reduction in all DVT rates
from 44% to 31%, as well as in proximal DVTs from
15% to 6%, with the use of enoxaparin. When stratifying
patients based on the presence of lower extremity frac-
tures however, only the fracture group displayed signifi-
cantly reduced proximal DVT rates (5% compared to
18.2%) while using enoxaparin. Because proximal DVTs
are associated with the majority of risk for PE, this
study suggests that in multisystem trauma, the benefit
of enoxaparin in preventing PE is mainly reserved for
those patients with lower extremity fractures. Current
American College of Chest Physicians (ACCP) practice
guidelines recommend LMWHs as soon as possible in
the absence of intracranial hemorrhage, uncontrolled
bleeding or incomplete spinal cord injury with an asso-
ciated hematoma [12].
Many clinicians still consider intracranial hemorrhage
(ICH) to be a contraindication for LMWH DVT prophy-
laxis. Denson and colleagues noted a 25% risk of VTE in
traumatic brain injured patients however, highlighting
the need for adequate prophylaxis. Studies by Kurtoglu
et al. [13] and Norwood et al. [14] have also challenged
this dogma by demonstrating that enoxaparin can be
safely used for DVT prophylaxis in patients with ICH. A
recently published prospective trial by Cothren el al.
[15] confirms this belief. This group demonstrated the
safety of LMWHs in head injury patients without
exacerbating intracranial bleeding. Complications asso-
ciated with LMWHs include bleeding and HIT.
Bleeding
Hemorrhagic complications of LMWH DVT prophylaxis
are varied. They range from a transient decrease in
hemoglobin levels to clinical bleeding requiring inter-
vention (angiography or surgery). These complications
are poorly defined in the literature and typically categor-
ized into two groups: fatal and non-fatal.
It has been suggested that LMWH increases the rate
of major bleeding during DVT prophylaxis. This was
not statistically supported by Geerts et al. [10] in spite
of the observation that patients receiving UH had fewer
major bleeding episodes compared to LMWHs (0.6% vs.
2.9% respectively). Bleeding was considered major when
it resulted in a hemoglobin drop of 2 or more grams
per deciliter, or more than two units of packed red
blood cells were transfused [10]. If a patient required
surgery as a consequence of DVT prophylaxis, or had
either an intracranial or retroperitoneal bleeding epi-
sode, it was also considered major [10]. In contrast, a
recent meta-analysis of 20,523 patients [16] showed that
LMWHs had fewer major bleeding events when com-
pared to both UHs and pentasaccharide, with relative
risks of 1.52 (95% CI, 1.04 - 2.23) and 1.52 (95% CI,
1.11 - 2.09) respectively. Only warfarin was observed to
have fewer major bleeding events than LMWHs (relative
risk = 0.59 (95% CI, 0.44 - 0.8)). The limitation of this
study however, was its inclusion of a mixed patient
population. As a result, the authors were unable to draw
direct conclusions regarding the LMWH bleeding risk
in trauma patients.
LMWHs and UHs were directly compared in three
publications. Green et al. [17] observed non-fatal bleed-
ing rates for LMWH and UH of 0% and 9.5% respec-
tively. They also reported 2 patients (9%) who died of
massive PE in the UH group, versus 0 patients in the
LMWH cohort. The overall event (bleeding or thrombo-
sis) rate was 0% in the LMWH group and 34% in the
UH group [17]. In contrast, Geerts et al. [10]
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2.9% and 0.6% respectively. There were no episodes of
fatal hemorrhage. In the Spinal Cord Injury Thrombo-
prophylaxis Investigators study, [18] the bleeding rate
for LMWH and UH was 2.6% and 5.3% respectively.
Using logistic regression analysis they identified age
greater than 50, low baseline hemoglobin, and shorter
duration of anticoagulant prophylaxis as predictive of
major bleeding events. Differences between the study
groups (polytrauma versus spinal cord injury patients)
may explain these varied rates (Table 1).
Among the trauma literature, there were six rando-
mized trials [10,13,17-20] comparing LMWHs to other
DVT prophylactic agents. All studies explicitly reported
bleeding complications. The pooled bleeding risk of
3.9% was slightly higher than the 3.1% reported in a
meta-analysis by Velmahos et al. [9]. In the same meta-
analysis the pooled calculated risk of bleeding using
UHs was comparable to LMWHs at 3.6%.
Although enoxaparin was the primary LMWH
employed in these studies, the trauma populations were
mixed, with some manuscripts analyzing spinal cord
trauma cohorts while others investigated general multi-
system trauma patients. When these publications were
analyzed separately, the pooled bleeding risk for spinal
cord trauma patients was 2.6% compared to 4.7% for
multi-system trauma patients. There were no episodes
of fatal bleeding reported in any study employing
LMWH DVT prophylaxis.
Heparin Induced Thrombocytopenia
HIT is an immune-mediated aggregation of platelets
leading to thrombocytopenia which has a high associa-
tion with the development of arterial and venous throm-
bosis. It is termed HIT, or previously white clot
Table 1 Summary of Randomized LMWH Trauma Studies which Report Bleeding Complications
Study Design Type of
LMWH
No.
Patients
Non-Fatal
Bleeding
Fatal
Bleeding
Geerts et al. 1996[10] Randomized
UH 5,000 U SC BID vs. LMWH 30 mg
SC BID
Enoxaparin 171* 5 (2.9%) 0
Multi-system trauma & ISS ≥ 9
Knudson et al. 1996[20] Randomized
LMWH 30 mg SC BID vs. SCD or AVI
bilaterally
Enoxaparin 120 6 (5%) 0
Multi-system trauma & AIS ≥ 3 with ISS
>1 0
Ginzburg et al. 2003[19] Randomized
LMWH 30 mg BID vs. IPC bilaterally Enoxaparin 218 13 (6%) 0
Multi-system trauma & ISS ≥ 9
Multi-system Trauma Bleeding Risk 24/509 (4.7%) 0%
Green et al. 1990[17] Randomized
UH 5,000 U SC TID vs. LMWH 3500 U
SC QD
Logiparin 20 0 0
Spinal cord trauma & complete motor
paraylsis
Spinal Cord Injury Thromboprophylaxis
Investigators 2003[18]
Randomized
UH 5,000 U SC TID + IPC vs. LMWH 30
mg SC BID
Enoxaparin 230 6 (2.6%) 0
Spinal cord trauma
Kurtoglu et al. 2004[13] Randomized
LMWH 40 mg QD vs. IPC bilaterally Enoxaparin 60 2 (3.3%) 0
Head and Spinal Trauma
Spinal Cord Trauma Bleeding Risk 8/310 (2.6%) 0%
Combined Total Bleeding Risk 32/819 (3.9%) 0%
* 344 patients randomized and assessed for bleeding whereas only 265 patients had venograms adequate for DVT analysis ISS, Injury Severity Score; SCD,
Sequential Compression Device; IPC, Intermittent Pneumatic Compression
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occurs between days 4 and 14 of heparin treatment.
Potentially fatal consequences, if not detected early, may
include thromboemolism, PE and bleeding [21]. The
HIT mechanism involves the development of IgG class
antibodies that bind heparin-platelet factor 4 (PF4) com-
plexes [22,23]. This antigen-antibody complex is thought
to mediate new thrombi formation and platelet
consumption.
The diagnosis of HIT consists of both clinical (throm-
bocytopenia) and serum detection (HIT antibodies).
Although the classic diagnosis of clinically significant
thrombocytopenia was a decrease in platelets below 150
×1 0
9/L, this definition may be inaccurate in the post-
operative or trauma patient population because they
often develop an acute phase reaction thrombocytosis.
The identification of corresponding antibodies also does
not guarantee a diagnosis of HIT because of its poor
specificity. Consequently, the latest definition [24] states
that clinically significant HIT occurs with an unex-
plained platelet decrease of over 50%, even when the
platelet count is greater than 150 × 10
9/L.
The incidence of developing HIT is variable depending
on both the duration of treatment and the patient popu-
lation. More specifically, the highest risk appears to
occur in cardiovascular surgery patients [25-28]. A
recent study by Lindhoff-Last et al. demonstrated the
incidence of HIT during the short-term use (5 to 7
days) of LMWHs to be 0%, whereas the rate was 0.53%
in the UH group [21]. A second cohort of patients trea-
ted long-term (28 days) with LMWHs also demon-
strated a 0.53% HIT incidence, similar to the UH group.
Warkentin et al. [29] randomized patients to either
LMWH (Enoxaparin) or UH DVT prophylaxis after hip
replacement surgery. This demonstrated a statistically
significant lower risk of HIT in patients on LMWH
when compared to UH, (0% versus 2.7% respectively).
When the modern definition of HIT was applied to this
study, the incidence of HIT for LMWH and UH chan-
ged to 0.6% and 4.8% respectively [24]. Lubenow et al.
[30] also identified a 0% incidence of HIT amongst 460
patients treated with LMWHs.
Although several studies have analyzed LMWHs in the
trauma population, few report the incidence of HIT.
Three publications [10,31,32] explicitly reported this
incidence during LMWH DVT prophylaxis in injured
patients. In this review, the pooled calculated rate of
HIT was 0.4% and therefore equal to the rate of 0.4%
reported by Velmahos et al. [9] in a recent meta-analy-
sis. In the meta-analysis, the pooled rate of HIT using
UH was 1.9% [9]. There were also two episodes of HIT
resulting in proximal vein thrombi identified by Geerts
et al. [10]. Unfortunately one study included in the
pooled calculation of this review is retrospective, [32]
making our analysis difficult. Furthermore, the original
raw data summarized in each manuscript is also not
available. Despite the minimal risk for HIT during
LMWH DVT prophylaxis, it is important that clinicians
follow platelet levels regularly in the care of injured
patients (Table 2).
Mechanical Device Complications
Mechanical device DVT prophylaxis is commonly uti-
lized in the setting of trauma because of its ease of use
and inherently low risk of associated bleeding. Mechani-
cal devices include graduated compression stockings
Table 2 Summary of LMWH Trauma Studies Explicitly Reporting Incidence of HIT
Study Design Type of LMWH No. Patients No. Cases of HIT
Geerts et al. 1996[10] Randomized
UH 5,000 U SC BID vs. LMWH 30 mg SC BID Enoxaparin 171 2
Multi-system trauma & ISS ≥ 9
Haentjens et al. 1996[31] Randomized
Fixed LMWH dose vs. Dose Adjusted LMWH Nadroparin 283 2
Orthopedic Trauma
Schwarcz et al. 2001[32] Retrospective
LMWH 30 mg SC BID Enoxaparin 234 1
Multi-system trauma
Lubenow et al. 2007[30] Prospective cohort Certoparin 460 0
LMWH 3000u OD
Multi-system trauma & orthopedic surgery
Total 5/1148 (0.4%)
HIT, Heparin Induced Thrombocytopenia
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ings and the venous foot pump (VFP). All three varia-
tions function by reducing the luminal diameter of a
vein resulting in an increase in venous flow velocity.
This increase in velocity theoretically reduces stasis and
decreases the risk of thrombus formation [33].
Compression devices are designed to apply pressure in
either a uniform or graduated fashion. Graduated stock-
ings offer a milking action to the leg and apply greatest
compression at the ankles. GCS provide a slightly longer
augmentation period, but there is no difference in peak
venous flow velocity between GCS and uniform com-
pression devices [34]. Despite a suggestion that GCS
may provide superior prophylaxis, they have not been
reported in the trauma population. IPC however, have
been studied in a randomized trial comparing IPC to
VFP in injured patients [35]. After randomizing 149
patients without lower extremity fractures, the authors
demonstrated a statistically significant decrease in the
incidence of DVT using IPC stockings as compared to
VFP (6.5% versus 21%). As a result, VFP appears to play
no role for DVT prophylaxis in trauma patients.
Two randomized trials also compared LMWHs to
mechanical device DVT prophylaxis [19,20]. Although
the incidence of DVT in the mechanical device groups
appeared higher when compared the LMWH cohorts, a
statistically significant DVT reduction was not identified.
Both studies conclude that mechanical devices are safe
and should be considered when anticoagulant DVT pro-
phylaxis is contraindicated.
Although frequently utilized for DVT prophylaxis, no
mechanical prophylaxis device has been shown to
reduce the rates of VTE or death. A recent trauma
meta-analysis by Velmahos failed to show any benefit of
IPC stockings compared to no prophylaxis [9]. Similarly,
a formal comparison between mechanical devices and
IVC filters has yet to be completed. Due to the lack of
level one evidence, ACCP guidelines recommend against
routine mechanical DVT prophylaxis in trauma patients
[12]. They may be considered in patients with a contra-
indication to anticoagulant VTE prophylaxis however
[12]. If mechanical devices are utilized, it is recom-
mended that either IPC or GCS be applied, since VFP
have demonstrated higher rates of associated DVTs [35].
Compression stockings are considered safer than phar-
macologic DVT prophylaxis because they minimize
bleeding risks. Despite a relatively low complication pro-
file, mechanical devices can still be associated with local
tissue injury, bleeding, and non-compliance.
Local Tissue Injury
The possibility of impairing subcutaneous tissue oxyge-
nation, particularly if patients suffer from peripheral vas-
cular compromise, has been previously identified [33].
Stockings of incorrect size may also place focal pressure
on skin resulting in tissue necrosis and ulceration. It has
been suggested that compression devices are relatively
contraindicated in patients with peripheral arterial dis-
ease and in diabetics suffering from peripheral neuropa-
thy. In fact, manufactures indicate that compression
devices should only be used if patients have ankle:bra-
chial indices greater that 0.7 [33].
Knudson et al. [20] has been the only group to report
local tissue damage data as a complication of IPC stock-
ings in trauma patients. Although they did not observe
pressure sores or ulceration, four patients had local skin
changes. This represents a rate of 2%. The rarity of
these reports suggests that this is either a rare event, or
under-appreciated. Four cases of peroneal nerve injury
associated with mechanical compression device DVT
prophylaxis have also been identified [36-38]. The pro-
posed mechanism of injury is nerve compression against
the fibular head. Although compartment syndrome is a
known complication among patients undergoing surgery
in the lithotomy position [36,39,40], there have been no
reports in trauma patients.
Bleeding
Bleeding is considered a rare complication of mechani-
cal DVT prophylaxis. Although the exact mechanism by
which mechanical devices cause bleeding is unclear, it is
postulated that activation of the fibrinolytic pathway
induces clot breakdown. It is also possible that the
bleeding events may have occurred regardless of
mechanical device use, and are therefore a reflection of
baseline risks. Three randomized trauma studies
[13,19,20] reported bleeding events in the mechanical
device group when compared to LMWHs. As a result,
mechanical devices have a lower calculated risk of
bleeding (2.6% vs. 4.7%)(Table 3).
Non-Compliance
Non-compliance is an indirect complication of mechani-
cal device DVT prophylaxis because it minimizes the
intended therapeutic effect. Several studies have demon-
strated poor compliance, from both patients and medi-
cal staff. In 1992, Comerota et al. [41] performed a
prospective study of 138 ICU patients considered high
risk for DVT. They demonstrated that 78% of patients
were compliant with mechanical device prophylaxis dur-
ing their ICU admission, however only 48% were com-
pliant when transferred to non-monitored units.
In the trauma population, Cornwell et al. [42] per-
formed a prospective analysis of patient compliance
using sequential compression device DVT prophylaxis.
They performed 6 observations over a 24-hour period
(morning, evening and overnight) for 227 high risk non-
ambulatory trauma patients. Full compliance was
defined as compression device use in all 6 observations.
They demonstrated only 19% of patients were fully com-
pliant and that the devices functioned correctly in only
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noon were associated with the poorest compliance.
Furthermore, during the periods of non-compliance,
61% of patients were awake. Patient and staff education
may improve mechanical device VTE prophylaxis com-
pliance [43].
Inferior Vena Cava Filter Complications
Pharmacologic and mechanical compression device DVT
prophylaxis can infrequently be contraindicated in the
trauma population. Pharmacologic prophylaxis is contra-
indicated in patients with intracranial hemorrhage,
bleeding solid organ injuries, recent spinal cord damage,
and ocular trauma. Furthermore, approximately one-
third of multi-system trauma patients suffer lower extre-
mity injuries precluding the use of mechanical compres-
sion devices. As a result, permanent prophylactic
inferior vena cava (IVC) filters have demonstrated a
decreased pulmonary embolism rate in a selected high-
risk trauma population [6,44-49]. Unfortunately all but
one study [47] were retrospective, and only two reported
long-term outcomes and complications [46,49].
In 2004, ACCP guidelines recommended against the
use of IVC filters as primary DVT prophylaxis. These
recommendations suggested IVC filter placement only
in patients with documented proximal DVT and an
absolute contraindication to full dose anticoagulation
therapy, or planned major surgery in the near future.
The absence of a well powered, randomized clinical trial
in the trauma population, as well as the unknown fre-
quency of long term complications (i.e. filter migration,
vena caval occlusion, and IVC penetration), have limited
the use of permanent prophylactic IVC filters.
A randomized trial by Decousus et al. [50] analyzed
the efficacy of permanent IVC filters in preventing PE in
non-trauma patients with known proximal DVT.
Observed short-term benefits in preventing PE were
unfortunately offset by long-term complications. This
reality has lead to an increased interest in temporary
and retrievable IVC filters. These devices offer the
immediate benefits of caval filtration when patients are
at their highest risk, but can be removed to prevent
long-term complications. Since 1986 [51] when the first
successful report of a retrievable IVC filter was pub-
lished, several studies have described success using tem-
porary IVC filters. Given that the majority of the trauma
population is young, the ability to remove the filters and
avoid potential long-term complications has made them
all the more attractive. Recent prospective [52,53] and
retrospective [54,55] studies suggest retrievable IVC fil-
ters are safe and effective in preventing PE in high risk
trauma patients. Until sufficient evidence outlining their
efficacy and cost-effectiveness is available however, they
will likely remain contraindicated for routine prophy-
laxis in the AACP guidelines [12]. Although routine use
is not indicated, a significant portion of trauma patients
will still require placement of these devices when other
forms of prophylaxis are contraindicated.
Complications related to IVC filter use fall into short
and long-term groups. Short term complications occur
during filter insertion, while long term complications
arise from the filter itself, as well as its chronic effects
on surrounding vasculature and blood flow (Table 4).
Permanent Filter Complications
Permanent filters are rarely indicated in the trauma
population due to the advent of retrievable filters, as
well as their ability to be converted to permanent filters
if required. However, since retrievable filter studies have
limited long term follow-up on patients with retrievable
filters converted to permanent, the majority of our
understanding of long term complications comes as a
result of permanent IVC filter studies.
i. Filter Migration
Filter migration is defined as cranial or caudal migration
greater than 10 mm [56]. In a long term study [57] 69
patients with permanent IVC filters in place for 1 to 9
Table 3 Summary of studies reporting bleeding events with mechanical device thromboprophylaxis
Study Design No. of Patients with IPC Non Fatal Bleeding Rate Fatal Bleeding Rate
Knudson et al. 1996[20] Randomized 61 0% 0%
SCD vs. LMWH 30 mg SC BID
Multi-system trauma, ISS > 10
Ginzburg et al. 2003[19] Randomized 224 8 (3.5%) 0%
IPC vs. LMWH 30 mg SC BID
Multi-system trauma, ISS ≥ 9
Kurtoglu et al. 2004[13] Randomized 60 1 (1.7%) 0%
IPC vs. LMWH 40 mg SC QD
Head & Spinal Trauma
Total 345 9 (2.6%) 0%
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cranial filter migrations were observed in 29% and 6% of
patients respectively. Although migration appears to be
a common event, its clinical significance is unclear.
Many studies have defined clinically significant filter
migration as those that became symptomatic. If a
patient develops a PE concurrent to filter migration,
they are also considered symptomatic. Cranial migration
can be symptomatic if it results in an acute myocardial
infarction secondary to movement into the right atrium.
Caudal migration is only significant when the filter
moves to the iliac vein resulting in less protection and a
symptomatic PE [58]. In a large single center 26 year
review of 1,753 patients (11.9% trauma) with permanent
IVC filters, Athanasoulis et al. [58] reported a sympto-
matic filter migration rate of 0.5% (9/1,753). Twenty-
two percent of these devices (2/9) migrated to the right
atrium. Both right atrial filters were retrieved percuta-
neously while a second filter was placed above the pri-
mary filter in the remaining 7 migrations. Routine
follow-up radiography was not performed to screen for
migration, therefore this rate is likely an underestimate.
In the trauma literature, five studies [46,47,49,59,60]
report long-term complications of permanent IVC fil-
ters. The overall calculated migration rate is 1.5% (Table
5), which is significantly higher than the 0.5% rate
reported in the largest non-trauma series. Although this
appears to be a relatively rare event, reported rates are
likely an underestimation because none of these studies
performed routine radiographic imaging to screen for
filter migration.
ii. IVC Occlusion
IVC occlusion secondary to thrombosis or trapped
emboli can lead to venostasis with lower extremity swel-
ling. It can also progress to hemodynamic instability.
Reported rates are variable (0.4% to 32.1%) and depend
upon the type of filter [58], patient population, and time
of investigation.
In the trauma literature, Greenfield et al. [59] reported
initial IVC occlusion rates between 2.3% and 3.5% for
therapeutic and prophylactic filters respectively. At the
last follow-up (mean = 2.1 years), IVC occlusion was 0%
and 1.4% respectively, suggesting IVC patency improves
over time. Similar observations in trauma patients by
both Patton et al. [60] and Langan et al. [46] identified
IVC occlusion rates of 0%. It must be noted however,
that these two studies are limited by a considerable loss
of patient follow-up (only 34% and 47% of patients
returned for evaluation). In a five year study of prophy-
lactic trauma IVC filters, Rogers et al. [49] reported 1, 2,
Table 4 List of Short and Long Term IVC Filter
Complications
Short Term Complications Long Term Complications
Inability to cannulate vein Filter migration
Arterial Puncture Filter tilting
Hematoma Filter strut fracture
Hemorrhage IVC perforation by struts
Air embolism IVC thrombosis
Pneumothorax Lower extremity swelling from venostasis
Hemothorax
Wound infection
Insertion site thrombosis
Misplaced filter
IVC perforation
Table 5 Summary of Studies Reporting Permanent IVC Filters Complications in a Trauma Population
Study Filter Type No. Patients Insertion
Complications*
Filter
Migration
Caval
Occlusion
IVC
Penetration
Greenfield et al. 2000
[59]
53% - Titanium GF 385 - Initial 24/385 (6%) 6/293 (2%) 7/293 (2.4%) 2/293 (0.6%)
47% - Stainless Steel GF 293 - Follow-
up
Patton et al. 1996[60] 100% - Titanium GF 110 - Initial 8/110 (7%) 1/110 (0.9%) 0/30 (0%) -
30 - Follow-up
Langan et al. 1999[46] Titanium (not reproted
%)
187 - Initial 3/187 (1.6%) 0/75 (0%) 0/70 (0%) 1/70 (1.4%)
Stainless Steel 75 - Follow-up
Rogers et al. 1998[49] 70% - Titanium GF 132 -Initial 4/132 (3%) - 1/47 (2%) -
16% - Stainless Steel GF 47 - Follow-up
8% - Vena Tech Filter
6% - Bird’s Nest Filter
Rodriguez et al. 1996
[47]
100% - Titanium GF 40 - Total - - 4/40 (10%) -
TOTAL 39/814 (4.8%) 7/473 (1.5%) 12/480 (2.5%) 3/363 (0.8%)
*Insertion Complications: Hematoma, Insertion Site DVT, Arterial Puncture, Pneumothorax, Misplaced IVC Filter, Deployment Errors, Puncture Site Infection
Note: GF = Greenfield Filter
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of IVC occlusion was reported by Rodriguez et al. [47]
who documented 10% of trauma patients (10/40) with
thrombi, although only 20% (2/10) were symptomatic
secondary to venostasis. Although IVC occlusion rates
appear relatively high in the short-term (2.3% to 10%),
the reduced long term rates (0% to 1.4%) suggest that
this is a rare long-term complication of permanent IVC
filtration.
iii. IVC Penetration
Filter struts possess the ability to erode through the IVC
wall inducing free perforation or contact with another
organ. Filter erosion appears to be dependent upon the
type of filter used. A study analyzing the Simon Nitinol
permanent filter by Poletti et al. [61] demonstrated that
95% of filter struts penetrated the IVC wall and 76%
contacted adjacent organs at 32 months follow-up. In a
small study evaluating Bird’s Nest Filters by Starok et
al., [62] there was 100% IVC wall penetration, although
all were clinically asymptomatic. The lowest reported
IVC penetration rate was by Greenfield et al. [63] which
followed 30 patients with a stainless steel Greenfield
IVC filter and demonstrated a 30% strut penetration
rate with no obvious clinical sequelae. All filter penetra-
tion was diagnosed on CT imaging [63]. Although these
studies report no clinical consequences of IVC perfora-
tion, Streiff et al. [56] identified that 0.4% of patients
develop symptoms.
Complications of strut perforation are rare, but
include duodenal perforation [64], aortic pseudoaneur-
ysm [65], retroperitoneal hematoma [66,67], ureteral
injury [68], and ruptured infrarenal aorta [69]. Although
early studies demonstrate a surprisingly high strut ero-
sion rate (between 30% and 100%), Kinney et al. [70]
recently reported a lower range of 9% to 24%. Despite
these values, the majority of patients remain asympto-
matic. This reality questions t h es i g n i f i c a n c eo ff i l t e r
strut IVC penetration.
Non-Permanent Filters
There are two categories of non-permanent filters: 1)
temporary filters, which are attached to a guide-wire or
catheter that protrudes externally and, 2) retrievable fil-
ters, which are deployed internally and have no external
component. Retrievable filters appear to be more applic-
able due to their ability to become permanent if
required. They also have lower infection rates secondary
to the absence of an external component. The majority
of complications attributable to retrievable filters are
related to insertion since long-term complications are
eliminated at the time of filter retrieval. Retrievable fil-
ters can become permanent however, and have the
added complication of failed retrieval, thus exposing the
patient to the long-term complications of permanent
IVC filtration.
There are currently three retrievable filters approved
by the Food and Drug Administration (FDA): 1)
Gunther Tulip (Cook, Inc., Bloomington, Indiana), 2)
Recovery Filter (Bard Peripheral Vascular, Inc., Tempe,
Arizona), and 3) OptEase (Cordis Endovascular, Warren,
New Jersey). Although retrieval time limits have yet to
be defined, most filters are removed within a few weeks.
The longest reported retrieval time in a trauma patient
was 317 days [71]. This retrieval required significant
force, with post-retrieval cavo g r a p h yr e v e a l i n gam i l d l y
stenosed IVC. This IVC subsequently returned to pre-
filter diameter within 3 months. Although there are sev-
eral studies which explicitly report retrievable filter com-
plications in non-trauma patients, [72-78] only four
studies analyzed their role in the trauma population
[52,55](Table 6).
Short-term complications of retrievable IVC filters in
non-trauma patients occur at a rate of 0% to 4.5%
[72-74,77,78], with a calculated rate of 2.6%. The six
insertion site complications reported by Rosenthal et al.
[55] included a femoral vein DVT, three misplaced IVC
filters into the right iliac vein, and two groin hemato-
Table 6 Summary of Studies Analyzing Retrievable IVC Filters in a Trauma Population
Study Filter
Type
No.
Patients
Duration of Insertion
(mean) (days) (range)
Insertion
Complication*
Filter
Migration
IVC
Penetration
Caval
Occlusion
Failed
Retrieval Rate
Rosenthal et al.
2004[55]
Optease 94 19 (5-25) 6 (6.4%) 0 1 0 0/31
Allen et al. 2005
[54]
Gunther
Tulip
51 NR 0/51 0 0 0 1/25 (4%)
Offner et al.
2003[53]
Gunther
Tulip
44 14 (3-30) 0/44 0 0 0 1/40 (2.5%)
Hoff et al. 2004
[52]
Gunther
Tulip
35 10 (6-14) 0/35 0 0 0 0/18
TOTAL 224 6/224 (2.6%) 0 1/224 (0.4%) 0 2/114 (2.8%)
*Insertion Complications: Hematoma, Insertion Site DVT, Arterial Puncture, Pneumothorax, Misplaced IVC Filter, Deployment Errors, Puncture Site Infection
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related complications, however all filters were placed at
the bedside under ultrasound guidance.
There is poor long-term follow-up data for trauma
patients with retrievable filters that were not removed.
In studies involving non-trauma patients with perma-
nent retrievable filters, filter migration occurred between
3% and 8%, and IVC occlusion rates were reported
between 4% and 15% [72-75,77,78]. Of the four studies
analyzing retrievable filters in injured patients, none
reported filter migration or IVC occlusion rates. One
patient did have a symptomatic IVC penetration for a
calculated rate of 0.4% however.
Failed filter retrieval does not carry an immediate com-
plication to the patient, but it does expose the patient to
the long-term complications of a permanent filter. Failed
retrieval rates in trauma patients are reported between
0% and 4% with a calculated rate of 2.8% (Table 6).
Conclusion
Pharmacologic anticoagulation using LMWHs is the
recommended primary thromboprophylaxis modality in
trauma patients. In this review we calculated the risk of
bleeding and HIT to be 3.9% and 0.7% respectively.
These values are slightly higher than the previously pub-
lished rates of 3.1% and 0.4% [9]. Mechanical compres-
sion device thromboprophylaxis should not be used as
an initial choice, however evidence supports its role in
trauma patients when LMWHs are contraindicated.
Mechanical devices have a generally safe profile, how-
ever they must be used with caution in patients with
peripheral vascular disease and peripheral neuropathy
for risks of soft tissue injury and ulceration. Although
the mechanism that predisposes patients to bleeding
while using mechanical devices is unclear, the calculated
risk of bleeding is 2.6%. This may reflect the general
risk of bleeding in a trauma patient. Patient compliance
is poor but may be improved with adequate patient and
staff education regarding the benefits of mechanical
thromboprophylaxis. When LMWH and mechanical
device thromboprophylaxis are contraindicated, retrieva-
ble IVC filters should be considered in high-risk trauma
patients [79]. Current high risk features include: spinal
cord injury with paraplegia or tetraplegia, severe brain
injury (Glascow Coma Score <8), multiple long bone
fractures and complex pelvic fractures [8]. Future stu-
dies are needed to identify the trauma populations that
will benefit from prophylactic IVC filtration. Retrievable
IVC filters have the benefit of providing protection from
PE in the early, high-risk period while consequently
being removed to prevent the long-term complications
of permanent IVC filtration. Although retrievable filters
are removed in the majority of patients, they may also
be left in place for permanent filtration if necessary. The
versatility of the retrievable filter has virtually eliminated
the use of permanent filters. Long-term follow-up stu-
dies of permanent IVC filtration using retrievable filters
are required. The risk of insertion related complications,
such as arterial puncture, hematoma, infection, and
pneumothorax is calculated to be 2.6%. There were no
reported filter migration or IVC occlusion events in the
short-term. Although a failed retrieval is not a direct
complication, it results in permanent IVC filtration and
places the patient at risk for future complications. The
failed retrieval rate is calculated to be 2.8%. While the
essential nature of thromboprophylaxis in the manage-
ment of multi-system trauma patients can not be under-
stated, understanding their potential complications is an
absolute requirement for both patient counselling and
clinical care.
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